Celis-Giraldo Carmen Teresa, López-Abán Julio, Muro Antonio, Patarroyo Manuel Alfonso, Manzano-Román Raúl
Molecular Biology and Immunology Department, Fundación Instituto de Inmunología de Colombia (FIDIC), Bogotá 111321, Colombia.
Animal Science Faculty, Universidad de Ciencias Aplicadas y Ambientales (U.D.C.A), Bogotá 111166, Colombia.
Vaccines (Basel). 2021 Sep 4;9(9):988. doi: 10.3390/vaccines9090988.
Nowadays, safe and efficacious vaccines represent powerful and cost-effective tools for global health and economic growth. In the veterinary field, these are undoubtedly key tools for improving productivity and fighting zoonoses. However, cases of persistent infections, rapidly evolving pathogens having high variability or emerging/re-emerging pathogens for which no effective vaccines have been developed point out the continuing need for new vaccine alternatives to control outbreaks. Most licensed vaccines have been successfully used for many years now; however, they have intrinsic limitations, such as variable efficacy, adverse effects, and some shortcomings. More effective adjuvants and novel delivery systems may foster real vaccine effectiveness and timely implementation. Emerging vaccine technologies involving nanoparticles such as self-assembling proteins, virus-like particles, liposomes, virosomes, and polymeric nanoparticles offer novel, safe, and high-potential approaches to address many vaccine development-related challenges. Nanotechnology is accelerating the evolution of vaccines because nanomaterials having encapsulation ability and very advantageous properties due to their size and surface area serve as effective vehicles for antigen delivery and immunostimulatory agents. This review discusses the requirements for an effective, broad-coverage-elicited immune response, the main nanoplatforms for producing it, and the latest nanovaccine applications for fighting animal pathogens.
如今,安全有效的疫苗是促进全球健康和经济增长的强大且具成本效益的工具。在兽医领域,这些无疑是提高生产力和抗击人畜共患病的关键工具。然而,持续感染病例、具有高变异性且快速演变的病原体或尚未开发出有效疫苗的新出现/重新出现的病原体表明,持续需要新的疫苗替代品来控制疫情爆发。现在,大多数已获许可的疫苗已成功使用多年;然而,它们存在内在局限性,如效力不一、有副作用以及一些缺点。更有效的佐剂和新型递送系统可能会提高疫苗的实际效力并及时推广应用。涉及纳米颗粒的新兴疫苗技术,如自组装蛋白、病毒样颗粒、脂质体、病毒体和聚合物纳米颗粒,为应对许多与疫苗开发相关的挑战提供了新颖、安全且具有高潜力的方法。纳米技术正在加速疫苗的发展,因为具有封装能力且因其尺寸和表面积而具有非常有利特性的纳米材料可作为抗原递送和免疫刺激剂的有效载体。本综述讨论了产生有效、广泛覆盖的免疫反应的要求、产生这种反应的主要纳米平台以及用于对抗动物病原体的最新纳米疫苗应用。